Medtronic reports strongest revenue growth in a decade, shares consolidate on NYSE

Medtronic reports its highest annual revenue growth in ten years and closes a busy fiscal 2026 with several portfolio moves, while NYSE-listed shares consolidate after a recent rebound.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 18:57.

Medtronic plc (IE00BTN1Y115) has reported its highest annual revenue growth in ten years for fiscal 2026, according to a recent company update cited by StockTitan, with the ordinary shares trading on the NYSE under the ticker MDT. This combination of robust top-line momentum and a steadily rebuilding share price puts the large-cap medical device name back in focus for health care equipment investors in the S&P 500 universe.

What the latest results show

Medtronic disclosed fourth quarter and full-year fiscal 2026 figures, with the company describing the year as delivering its strongest annual revenue growth in a decade. While exact growth percentages are not broken out in the StockTitan summary, the characterization marks a clear uptick from the muted expansion that had weighed on the stock in previous years.

The earnings headline sits alongside several recent strategic announcements, including an intent to acquire SPR Therapeutics to expand care options for people living with chronic pain, and investments to support future expansion of its cardiac ablation portfolio. These deals and capital commitments are designed to deepen Medtronic’s footprint in neurovascular and electrophysiology markets, areas where peers like Boston Scientific seek similar growth.

Analysts and price performance picture

Analyst data aggregated by wallstreet-online shows a diversified rating profile on Medtronic, with 38 percent of analysts assigning a Strong Buy, 16 percent a Buy, 41 percent a Hold, and 4 percent each a Sell or Strong Sell rating, for an overall score of 3.81 out of 5. This mix reflects cautious optimism: upside potential is seen, but the consensus stops short of a uniformly bullish stance.

In euro terms, Medtronic shares trade at 70.65 euros as of 16:38:02 on wallstreet-online, up 2.04 percent over the past 24 hours, with a seven-day gain of 1.91 percent and a 30-day rise of 2.98 percent. Over twelve months the stock shows a negative performance of 15.41 percent and sits 24.34 percent below its 52-week high, while still 10.14 percent above its 52-week low, underscoring a recovery from recent troughs but leaving room before prior levels are reclaimed.

The product behind the stock

Medtronic’s core business centers on medical devices across cardiology, neurology and surgery, with a prominent example being its implantable cardiac pacemakers and cardioverter-defibrillators. These devices help manage arrhythmias and heart failure, and are complemented by cardiac resynchronization systems, ablation tools and implantable monitors that support long-term disease management in hospitals and outpatient settings.

Where the shares trade today

The Medtronic shares (IE00BTN1Y115) trade on the New York Stock Exchange under the ticker MDT, with a recent reference price of 79.27 US dollars as of 2026-06-22 according to StockTitan. In parallel, the Frankfurt-linked quote on wallstreet-online shows 70.65 euros at 16:38:02, offering a euro-denominated view for German investors.

Medtronic in brief

• Company: Medtronic plc
• ISIN: IE00BTN1Y115
• WKN: A14M2J
• Ticker: MDT
• Trading venue: NYSE
• Price (as of 2026-06-22, 16:38): 79.27 US dollars
• Market cap: approximately 106 billion US dollars (as of late June 2026, based on MDT quote and common data providers).
• Sector / industry: Health Care Equipment & Supplies
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any kind. All data are based on sources cited and checked at the time of publication and may change without notice.